Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

@article{Primrose2014SystemicCW,
  title={Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.},
  author={John Neil Primrose and Stephen J. Falk and Meg Finch-Jones and Juan W Valle and D O'reilly and A K Siriwardena and Joanne Hornbuckle and Mark Peterson and Myrddin Rees and Tim Iveson and Tamas Hickish and Rachel K. Butler and Louise Stanton and Elizabeth C Dixon and Louisa Little and Megan Bowers and Si{\^a}n A Pugh and Oliver J Garden and David C. Cunningham and Tim Maughan and John A Bridgewater},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 6},
  pages={601-11}
}
BACKGROUND Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of oxaliplatin and fluorouracil chemotherapy. The addition of cetuximab to these chemotherapy regimens results in an overall survival advantage in patients with advanced disease who have the KRAS exon 2 wild-type tumour genotype. We aimed to assess the benefit of addition of cetuximab to standard chemotherapy in patients with… CONTINUE READING